ジペプチドペプチダーゼ4阻害剤の2030年までの世界市場予測： 薬剤タイプ別、用途別、地域別の世界分析

Stratistics MRCによると、ジペプチジルペプチダーゼ4阻害剤の世界市場は2023年に113億米ドルを占め、予測期間中のCAGRは4.8％で成長し、2030年には156億9,000万米ドルに達すると予測されています。

ジペプチジルペプチダーゼ4（DPP-4）阻害剤と呼ばれる薬剤クラスは、2型糖尿病の治療に使用されます。DPP-4という酵素は、血糖値のコントロールに不可欠なインクレチンホルモンの分解を担っています。これらの薬剤はDPP-4を阻害することにより、インクレチンホルモン、特にグルカゴン様ペプチド-1（GLP-1）の作用を増強し、インスリン分泌を高め、グルカゴン産生を低下させる。その結果、血糖値が下がり、グルコースの調節が強化されます。

米国糖尿病学会によると、ジペプチジルペプチダーゼ4（DPP-4）阻害薬は、2型糖尿病の管理にとって貴重な薬物です。これらの阻害剤は、DPP-4酵素を標的とすることにより、インクレチンホルモンの効果を増強し、血糖コントロールの改善に寄与します。

糖尿病罹患率の上昇

ジペプチジルペプチダーゼ4（DPP-4）阻害剤の市場は、世界の糖尿病罹患率の上昇によって大きく牽引されています。2030年までに、世界中で5億3,700万人が糖尿病に罹患すると推定されており、効率的な糖尿病治療薬に対するニーズが高まっています。さらに、DPP-4阻害剤は2型糖尿病患者に有効な治療選択肢を提供することでこのニーズに応え、市場全体の成長に寄与しています。

潜在的な安全性の問題

ジペプチジルペプチダーゼ4（DPP-4）阻害薬は、一般的に良好な安全性プロファイルを有するにもかかわらず、安全性に関する懸念がいくつか指摘されています。膵炎や関節痛など、まれではあるが危険な副作用が報告されているため、患者や医療従事者は特定の薬剤の服用に消極的になる可能性があります。さらに、DPP-4阻害剤の業界内での持続的な信頼性と承認を保証するためには、これらの可能性のある危険性を認識し、理解することが不可欠です。

治療ガイドラインと適応症の拡大

ジペプチジルペプチダーゼ4（DPP-4）阻害剤の潜在的な可能性としては、治療ガイドラインの更新や適応症の拡大が挙げられます。さらに、特定の患者集団や他の治療法との併用におけるDPP-4阻害薬の利点を検討する調査や臨床試験が進行中であることから、適応の拡大や市場成長・採用への新たな道が開ける可能性があります。

価格圧力とジェネリック医薬品の侵食

ブランド薬の特許が切れた場合、DPP-4阻害薬市場はジェネリック医薬品の侵食という課題に直面します。通常より安価なジェネリック医薬品が利用できるようになると、価格圧力が高まる可能性があります。さらに、先発品を製造している製薬会社は、この現象により収益性が低下し、研究開発やマーケティング資源への投資に影響を及ぼす可能性があります。

COVID-19の影響：

ジペプチジルペプチダーゼ4（DPP-4）阻害薬市場は、COVID-19の大流行によって様々な影響を受けています。処方パターンや患者のアドヒアランスは、患者の優先順位の変化、医療システムの混乱、財政難などの影響を受けています。遠隔医療の導入は劇的に増加し、患者との交流や医薬品販売の従来の力学に影響を与えています。さらに、抗糖尿病薬の需要が堅調に推移しているにもかかわらず、市場は変動しています。このことは、世界の健康危機の継続的な影響に対処するために、製薬企業が革新的で柔軟な姿勢を維持する必要性を浮き彫りにしています。

予測期間中、シタグリプチンセグメントが最大となる見込み

シタグリプチンセグメントが最大の市場シェアを占めると予測されます。複数のブランド名で販売されているシタグリプチンは、2型糖尿病の治療薬として一般的に処方されています。DPP-4酵素を阻害することで作用し、血糖値を大幅に低下させる。良好な安全性プロファイル、経口投与が容易であること、血糖コントロール改善効果が証明されていることなどが人気の理由です。さらに、シタグリプチンは、その幅広い使用法と豊富な臨床経験により、DPP-4阻害薬市場で確固たる地位を築いています。

予測期間中にCAGRが最も高くなると予想されるのはクリニックセグメント

市場のCAGRが最も高いのはクリニックセグメントです。このパターンは、患者の嗜好や医療提供方法の変化を示しています。クリニックは、定期検診、予防医療、専門治療など、さまざまな医療サービスを提供する場として、ますます人気が高まっています。クリニックの特徴は、より簡単にアクセスでき、便利な医療サービスを提供できることです。クリニックの急速な拡大の背景には、外来診療に対するニーズの高まりと、個別化された地域密着型の医療が重視されるようになったことがあります。さらに、効率性、待ち時間の短さ、患者に提供する個別ケアにより、クリニックはより急速に成長しています。

最大のシェアを持つ地域

ジペプチドペプチダーゼ4（DPP-4）阻害剤の市場シェアは北米が最も高いです。DPP-4阻害剤と呼ばれる薬剤クラス別は、2型糖尿病の治療薬として処方されます。北米がDPP-4阻害薬市場のかなりの部分を占めているのにはいくつかの理由があります。まず、この地域では2型糖尿病の罹患率が高いため、効率的な治療オプションの必要性が高まっています。米国疾病予防管理センター（CDC）によれば、米国人の糖尿病患者の大半、約3,400万人が2型糖尿病です。さらに北米は、製薬会社、最先端の医療研究施設、規制の枠組みなど、確立された医療インフラを誇っています。

CAGRが最も高い地域：

ジペプチドペプチダーゼ4（DPP-4）阻害薬市場は、アジア太平洋で最も高いCAGRが見込まれています。DPP-4阻害剤と呼ばれる薬剤クラス別は、2型糖尿病の治療に処方されます。アジア太平洋には、中国、インド、日本、オーストラリアなどが含まれます。アジア太平洋のDPP-4阻害剤市場は、さまざまな要因によって急成長しています。この地域には、2型糖尿病を発症するリスクのある人や、すでに発症していると診断された人が多く、人口が急速に増加しています。さらに、DPP-4阻害剤などの糖尿病治療薬には、この人口動向によって大きな市場が形成されています。

無料カスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます。

• 企業プロファイル
  • 追加市場参入企業の包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推定・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データ鉱業
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査ソース
  • 1次調査ソース
  • 2次調査ソース
  • 前提条件

第3章 市場動向分析

• イントロダクション
• 促進要因
• 抑制要因
• 機会
• 脅威
• 用途分析
• 新興市場
• 新型コロナウイルス感染症（COVID-19）の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界のジペプチドペプチダーゼ4阻害剤市場：薬剤タイプ別

• イントロダクション
• シタグリプチン
• ビルダグリプチン
• サクサグリプチン
• リナグリプチン
• ゲミグリプチン
• アナグリプチン
• テネリグリプチン
• その他

第6章 世界のジペプチドペプチダーゼ4阻害剤市場：用途別

• イントロダクション
• 病院
• クリニック
• その他

第7章 世界のジペプチドペプチダーゼ4阻害剤市場：地域別

• イントロダクション
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他の欧州
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他のアジア太平洋
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他の南米
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他の中東・アフリカ

第8章 主要発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品の発売
• 事業拡大
• その他の主要戦略

第9章 企業プロファイル

• Merck
• Boehringer Ingelheim
• Novartis
• AstraZeneca
• GlaxoSmithKline
• Eli Lilly and Company
• Pfizer
• Sanofi
• Bristol-Myers Squibb
• Takeda Pharmaceuticals

List of Tables

• Table 1 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 3 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Sitagliptin (2021-2030) ($MN)
• Table 4 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Vildagliptin (2021-2030) ($MN)
• Table 5 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Saxagliptin (2021-2030) ($MN)
• Table 6 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Linagliptin (2021-2030) ($MN)
• Table 7 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Gemigliptin (2021-2030) ($MN)
• Table 8 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Anagliptin (2021-2030) ($MN)
• Table 9 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Teneligliptin (2021-2030) ($MN)
• Table 10 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Other Drug Types (2021-2030) ($MN)
• Table 11 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Application (2021-2030) ($MN)
• Table 12 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 13 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Clinics (2021-2030) ($MN)
• Table 14 Global Dipeptide Peptidase 4 Inhibitor Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 15 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Country (2021-2030) ($MN)
• Table 16 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 17 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Sitagliptin (2021-2030) ($MN)
• Table 18 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Vildagliptin (2021-2030) ($MN)
• Table 19 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Saxagliptin (2021-2030) ($MN)
• Table 20 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Linagliptin (2021-2030) ($MN)
• Table 21 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Gemigliptin (2021-2030) ($MN)
• Table 22 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Anagliptin (2021-2030) ($MN)
• Table 23 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Teneligliptin (2021-2030) ($MN)
• Table 24 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Other Drug Types (2021-2030) ($MN)
• Table 25 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Application (2021-2030) ($MN)
• Table 26 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 27 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Clinics (2021-2030) ($MN)
• Table 28 North America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 29 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Country (2021-2030) ($MN)
• Table 30 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 31 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Sitagliptin (2021-2030) ($MN)
• Table 32 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Vildagliptin (2021-2030) ($MN)
• Table 33 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Saxagliptin (2021-2030) ($MN)
• Table 34 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Linagliptin (2021-2030) ($MN)
• Table 35 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Gemigliptin (2021-2030) ($MN)
• Table 36 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Anagliptin (2021-2030) ($MN)
• Table 37 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Teneligliptin (2021-2030) ($MN)
• Table 38 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Other Drug Types (2021-2030) ($MN)
• Table 39 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Application (2021-2030) ($MN)
• Table 40 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 41 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Clinics (2021-2030) ($MN)
• Table 42 Europe Dipeptide Peptidase 4 Inhibitor Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 43 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Country (2021-2030) ($MN)
• Table 44 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 45 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Sitagliptin (2021-2030) ($MN)
• Table 46 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Vildagliptin (2021-2030) ($MN)
• Table 47 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Saxagliptin (2021-2030) ($MN)
• Table 48 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Linagliptin (2021-2030) ($MN)
• Table 49 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Gemigliptin (2021-2030) ($MN)
• Table 50 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Anagliptin (2021-2030) ($MN)
• Table 51 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Teneligliptin (2021-2030) ($MN)
• Table 52 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Other Drug Types (2021-2030) ($MN)
• Table 53 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Application (2021-2030) ($MN)
• Table 54 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 55 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Clinics (2021-2030) ($MN)
• Table 56 Asia Pacific Dipeptide Peptidase 4 Inhibitor Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 57 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Country (2021-2030) ($MN)
• Table 58 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 59 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Sitagliptin (2021-2030) ($MN)
• Table 60 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Vildagliptin (2021-2030) ($MN)
• Table 61 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Saxagliptin (2021-2030) ($MN)
• Table 62 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Linagliptin (2021-2030) ($MN)
• Table 63 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Gemigliptin (2021-2030) ($MN)
• Table 64 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Anagliptin (2021-2030) ($MN)
• Table 65 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Teneligliptin (2021-2030) ($MN)
• Table 66 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Other Drug Types (2021-2030) ($MN)
• Table 67 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Application (2021-2030) ($MN)
• Table 68 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 69 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Clinics (2021-2030) ($MN)
• Table 70 South America Dipeptide Peptidase 4 Inhibitor Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 71 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Country (2021-2030) ($MN)
• Table 72 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Drug Type (2021-2030) ($MN)
• Table 73 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Sitagliptin (2021-2030) ($MN)
• Table 74 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Vildagliptin (2021-2030) ($MN)
• Table 75 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Saxagliptin (2021-2030) ($MN)
• Table 76 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Linagliptin (2021-2030) ($MN)
• Table 77 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Gemigliptin (2021-2030) ($MN)
• Table 78 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Anagliptin (2021-2030) ($MN)
• Table 79 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Teneligliptin (2021-2030) ($MN)
• Table 80 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Other Drug Types (2021-2030) ($MN)
• Table 81 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Application (2021-2030) ($MN)
• Table 82 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 83 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Clinics (2021-2030) ($MN)
• Table 84 Middle East & Africa Dipeptide Peptidase 4 Inhibitor Market Outlook, By Other Applications (2021-2030) ($MN)

According to Stratistics MRC, the Global Dipeptide Peptidase 4 Inhibitor Market is accounted for $11.3 billion in 2023 and is expected to reach $15.69 billion by 2030 growing at a CAGR of 4.8% during the forecast period. A class of drugs called dipeptidyl peptidase 4 (DPP-4) inhibitors is used to treat type 2 diabetes. The enzyme DPP-4 is responsible for the breakdown of incretin hormones, which are essential for controlling blood sugar levels. These drugs work by blocking DPP-4, which increases the effect of incretins, specifically glucagon-like peptide-1 (GLP-1), which raises insulin secretion and lowers glucagon production. As a result, blood sugar levels are lowered, and glucose regulation is enhanced.

According to the American Diabetes Association, Dipeptidyl Peptidase 4 (DPP-4) Inhibitors represent a valuable class of medications for the management of type 2 diabetes. These inhibitors, by targeting the DPP-4 enzyme, enhance the effectiveness of incretin hormones, contributing to improved blood sugar control.

Market Dynamics:

Driver:

Rising incidence of diabetes

The market for dipeptidyl peptidase 4 (DPP-4) inhibitors is significantly driven by the ongoing worldwide rise in the prevalence of diabetes. By 2030, there will be 537 million people worldwide estimated to have diabetes, creating a growing need for efficient diabetes medications. Furthermore, DPP-4 inhibitors meet this need by providing a workable treatment option for individuals with type 2 diabetes, thereby contributing to the overall growth of the market.

Restraint:

Potential safety issues

Dipeptidyl Peptidase 4 (DPP-4) inhibitors have raised some safety concerns despite having a generally good safety profile. Patients and healthcare professionals may be reluctant to take certain medications due to reports of uncommon but dangerous side effects, such as pancreatitis and joint pain. Moreover, it is imperative to acknowledge and comprehend these possible hazards in order to guarantee the sustained credibility and approval of DPP-4 inhibitors within the industry.

Opportunity:

Extending treatment guidelines and indications

Potential opportunities for Dipeptidyl Peptidase 4 (DPP-4) inhibitors include the inclusion of these drugs in updated treatment guidelines and the possible expansion of their indications. Additionally, expansion of indications and new paths for market growth and adoption may result from ongoing research and clinical trials examining the advantages of DPP-4 inhibitors in particular patient populations or in conjunction with other therapies.

Threat:

Price pressures and generic erosion

When the patents for branded drugs expire, the DPP-4 inhibitor market faces challenges from the threat of generic erosion. Price pressure may increase when generic alternatives, which are usually provided at a lower cost, are available. Furthermore, pharmaceutical companies that produce the branded versions may see a decrease in profitability as a result of this phenomenon, which could have an effect on their investment in R&D and marketing resources.

Covid-19 Impact:

The Dipeptidyl Peptidase 4 (DPP-4) inhibitor market has been impacted by the COVID-19 pandemic in many ways. Prescription patterns and patient adherence have been impacted by changes in patient priorities, disruptions in healthcare systems, and financial difficulties. The adoption of telehealth has increased dramatically, impacting the conventional dynamics of patient interactions and pharmaceutical sales. Additionally, the market has fluctuated even though the demand for anti-diabetic drugs has remained strong. This highlights the need for pharmaceutical companies to remain innovative and flexible in order to deal with the ongoing effects of the global health crisis.

The Sitagliptin segment is expected to be the largest during the forecast period

It is projected that the sitagliptin segment will have the largest market share. Sitagliptin, sold under several brand names, is a commonly prescribed drug for the treatment of type 2 diabetes. It works by inhibiting the DPP-4 enzyme, which significantly lowers blood sugar levels. Its favorable safety profile, ease of oral administration, and proven ability to improve glycemic control are the reasons for its popularity. Moreover, sitagliptin has a strong hold in the DPP-4 inhibitor market thanks to its broad usage and wealth of clinical experience.

The Clinics segment is expected to have the highest CAGR during the forecast period

The market's highest CAGR has been seen in the clinic segment. This pattern points to a change in patient preferences and the ways that healthcare is delivered. Clinics are becoming more and more popular for offering a variety of medical services, such as regular check-ups, preventive care, and specialized treatments. They are distinguished by their more easily accessible and convenient healthcare services. The rapid expansion of clinics has been driven by the growing need for outpatient care as well as the growing emphasis on individualized and community-based healthcare. Additionally, clinics are growing more rapidly because of the efficiency, shorter wait times, and individualized care they provide to their patients.

Region with largest share:

North America holds the largest market share for dipeptide peptidase 4 (DPP-4) inhibitors. A class of drugs called DPP-4 inhibitors is prescribed to treat type 2 diabetes. For a number of reasons, North America commands a sizable portion of the DPP-4 inhibitor market. First off, the need for efficient treatment options is fueled by the high rate of type 2 diabetes in the area. The majority of Americans with diabetes, approximately 34 million, have type-2 diabetes, according to the Centers for Disease Control and Prevention (CDC). Furthermore, North America also boasts a well-established healthcare infrastructure, which includes pharmaceutical companies, cutting-edge medical research facilities, and regulatory frameworks.

Region with highest CAGR:

The dipeptide peptidase 4 (DPP-4) inhibitor market is anticipated to grow at the highest CAGR in the Asia-Pacific region. A class of drugs called DPP-4 inhibitors is prescribed to treat type 2 diabetes. The nations of China, India, Japan, Australia, and other countries are included in the Asia-Pacific region. The Asia-Pacific DPP-4 inhibitor market is growing at a rapid rate due to a number of factors. There are many people in the area who are either at risk of developing type-2 diabetes or who have already been diagnosed with the disease, and the population is growing quickly. Moreover, a sizeable market is created for diabetes drugs, such as DPP-4 inhibitors, by this demographic trend.

Key players in the market

Some of the key players in Dipeptide Peptidase 4 Inhibitor market include Merck, Boehringer Ingelheim, Novartis, AstraZeneca, GlaxoSmithKline, Eli Lilly and Company, Pfizer, Sanofi, Bristol-Myers Squibb and Takeda Pharmaceuticals.

Key Developments:

In February 2024, Novartis announced that it has entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG, a Germany-based, global biopharmaceutical company developing innovative medicines in oncology. According to a press statement, the acquisition, which is subject to customary closing conditions, including a minimum acceptance threshold of 65 percent of outstanding shares tendered in the takeover offer and regulatory approvals.

In February 2024, Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA announced that it has signed a definitive agreement to acquire the aqua business of Elanco Animal Health Incorporated for $1.3 billion in cash, consisting of an innovative portfolio of medicines and vaccines, nutritionals and supplements for aquatic species; two related aqua manufacturing facilities in Canada and Vietnam; as well as a research facility in Chile.

In November 2023, Boehringer Ingelheim and IBM announced an agreement that will enable Boehringer to use IBM's foundation model technologies to discover novel candidate antibodies for the development of efficient therapeutics. Boehringer will be using an IBM-developed, pre-trained AI model that will be further fine-tuned on additional Boehringer proprietary data.

Drug Types Covered:

• Sitagliptin
• Vildagliptin
• Saxagliptin
• Linagliptin
• Gemigliptin
• Anagliptin
• Teneligliptin
• Other Drug Types

Applications Covered:

• Hospitals
• Clinics
• Other Applications

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Dipeptide Peptidase 4 Inhibitor Market, By Drug Type

• 5.1 Introduction
• 5.2 Sitagliptin
• 5.3 Vildagliptin
• 5.4 Saxagliptin
• 5.5 Linagliptin
• 5.6 Gemigliptin
• 5.7 Anagliptin
• 5.8 Teneligliptin
• 5.9 Other Drug Types

6 Global Dipeptide Peptidase 4 Inhibitor Market, By Application

• 6.1 Introduction
• 6.2 Hospitals
• 6.3 Clinics
• 6.4 Other Applications

7 Global Dipeptide Peptidase 4 Inhibitor Market, By Geography

• 7.1 Introduction
• 7.2 North America
  • 7.2.1 US
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 Italy
  • 7.3.4 France
  • 7.3.5 Spain
  • 7.3.6 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 Japan
  • 7.4.2 China
  • 7.4.3 India
  • 7.4.4 Australia
  • 7.4.5 New Zealand
  • 7.4.6 South Korea
  • 7.4.7 Rest of Asia Pacific
• 7.5 South America
  • 7.5.1 Argentina
  • 7.5.2 Brazil
  • 7.5.3 Chile
  • 7.5.4 Rest of South America
• 7.6 Middle East & Africa
  • 7.6.1 Saudi Arabia
  • 7.6.2 UAE
  • 7.6.3 Qatar
  • 7.6.4 South Africa
  • 7.6.5 Rest of Middle East & Africa

8 Key Developments

• 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 8.2 Acquisitions & Mergers
• 8.3 New Product Launch
• 8.4 Expansions
• 8.5 Other Key Strategies

9 Company Profiling

• 9.1 Merck
• 9.2 Boehringer Ingelheim
• 9.3 Novartis
• 9.4 AstraZeneca
• 9.5 GlaxoSmithKline
• 9.6 Eli Lilly and Company
• 9.7 Pfizer
• 9.8 Sanofi
• 9.9 Bristol-Myers Squibb
• 9.10 Takeda Pharmaceuticals